Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2012

View Archived Issues

BMS and Duke Translational Medicine Institute broaden their collaboration

Researchers identify biomarker for ulcer-type interstitial cystitis

Potassium channel blocker has antiobesity effects in animal models

Collaborating Australian universities design new candidate schizophrenia therapies

New marker and potential therapeutic target identified for castration-resistant prostate cancer

AVI BioPharma clear to proceed with studies of AVI-6003 component

Merck & Co. designs new products with potential to treat hepatitis C

Amgen divulges novel beta-secretase 1 inhibitors

Novel ALK inhibitors created with anticancer potential

Merck KGaA reports new P70S6K inhibitors

Novel protease-activated PAR2 receptor ligands developed in Australia

New protein kinase inhibitors identified at Nerviano Medical Sciences

Dainippon Sumitomo Pharma reaches agreement on acquisition

OncoTherapy Science updates on cancer peptide vaccine pipeline

BCI-838 enters new phase I trial

Shire and arGEN-X to develop therapeutic antibodies for rare diseases

Creabilis begins phase IIb CT-327 study

Biotie completes PET imaging study of serotonin 5-HT6 receptor antagonist

Essentialis reports results from phase IIb trial of DCCR

Baxter International begins study of stem cell therapy for chronic myocardial ischemia

FDA accepts Tau Therapeutics' IND for repositioned drug

Johns Hopkins and ImmunoCellular Therapeutics enter licensing agreement for cancer antigen

Polaris begins dosing in study of cancer therapy in pediatric patients

Global rights to biocrea phosphodiesterase program transferred

FDA grants orphan drug status to treatment for lysosomal storage disorder

Avanir and Concert Pharmaceuticals to develop deuterium-modified dextromethorphan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...